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Background/aim: Compared to healthy controls, mean platelet volume (MPV) is frequently higher in patients with Familial
Mediterranean fever (FMF) but lower in AA amyloidosis patients. The reason for the difference in MPV levels in FMF patients with and
without AA amyloidosis is unclear. The aim of the study was to determine whether low MPV is unique to AA amyloidosis or MPV is
similarly low in all glomerular diseases as a result of proteinuria and/or renal dysfunction.
Materials and methods: We compared pre-biopsy MPV levels of patients with AA amyloidosis secondary to FMF, to MPV levels of
patients with membranous glomerulonephritis, focal segmental glomerulosclerosis (FSGS) and IgA nephropathy that all present with
proteinuria and renal dysfunction.
Results: 703 patients (411 male, 292 female) were included in the study. Mean age was 42.6  14.3 years. There were 124 patients
with AA amyloidosis, 224 patients with IgA nephropathy, 188 patients with membranous glomerulonephritis, and 167 patients with
FSGS. Patients with AA amyloidosis had lower MPV levels compared to patients without AA amyloidosis (7.9  1.2 fL vs. 8.2  0.9 fL
respectively, p = 0.008). Patients with AA amyloidosis had significantly lower MPV compared to patients with each of the other
diagnoses. Independent predictors of MPV were platelet count (β = –0.321, p < 0.001) and CRP (β = – 0.134, p < 0.03).
Conclusion: This study is the largest study of MPV in patients with biopsy proven AA amyloidosis and confirms previous studies
reporting low MPV in AA amyloidosis. This study indicates that low MPV in AA amyloidosis cannot be explained with proteinuria and
renal dysfunction.
Key words: AA amyloidosis, familial Mediterranean fever, glomerulonephritis, mean platelet volume

1. Introduction
Familial
Mediterranean
fever
(FMF)
is
an
autoinflammatory disease characterized by self-limiting
recurrent attacks of fever, serositis and arthritis [1,2]. It is
prevalent in Turks, Jews, Armenians, and Arabs [3].
Colchicine and antiinterleukin 1 drugs are the main
treatment options and prevent both the symptomatic
attacks and also the development of AA amyloidosis [4,5].
Once amyloidosis develops in untreated or drug-resistant
patients, the course is characterized by severe nephrotic
syndrome and progressive renal dysfunction leading to
end stage renal disease.
Mean platelet volume (MPV) is routinely reported
during complete blood count examinations and regarded
as a marker of platelet function and activity [6]. Since
inflammation has a direct effect on platelet reactivity and
platelet volume, MPV had been widely evaluated in
patients with FMF. However, there are discrepancies
among the results of the studies. Although most of the
studies revealed higher MPV levels in FMF patients
compared to the control group [7–12], some other studies

reported similar [13,14] or even lower MPV levels in FMF
patients [15, 16].
On the other hand, previous studies consistently
revealed lower MPV levels in patients with FMF related
AA amyloidosis compared to FMF patients without AA
amyloidosis or healthy controls [10,17]. The cause of
differing MPV levels in FMF patients with and without AA
amyloidosis and also mechanism of low MPV in AA
amyloidosis is not clear.
Since the most striking clinical differences in FMF
patients with and without AA amyloidosis are renal
dysfunction and severe proteinuria that is commonly in
the nephrotic range, we hypothesized that these
parameters could be responsible from low MPV in
patients with FMF related AA amyloidosis in contrast to
FMF patients without AA amyloidosis. Therefore, we
aimed to determine whether low MPV is unique to AA
amyloidosis or MPV is similarly low in commonly seen
glomerular
diseases
including
membranous
glomerulonephritis, focal segmental glomerulosclerosis
(FSGS), and IgA nephropathy that all present with
proteinuria and renal dysfunction.
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2. Materials and methods
In this retrospective study we evaluated the reports of all
kidney biopsies performed in Hacettepe University
Medical Faculty Nephrology Department between 1
January 2001 and 1 January 2018. The patients who were
> 18 years old at the time of biopsy and diagnosed with
membranous glomerulonephritis, FSGS, IgA nephropathy
or AA amyloidosis secondary to FMF as a result of these
biopsies were included in the study. Patients with more
than one diagnoses in renal biopsy examinations were
excluded. Patients under any immunosuppressive
treatment including patients with a previous diagnosis of
glomerulonephritis that underwent control biopsy were
also excluded. Diagnosis of FMF was made according to
the Tel–Hashomer criteria [2].
A total of 703 patients were included in the analysis. In
addition to demographic parameters and pathological
diagnosis; hemoglobin, leukocyte, thrombocyte values,
and MPV levels measured in complete blood counts taken
before the procedure on the morning of biopsy, and the
most recent serum creatinine, albumin, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), and
24-h urine protein values before biopsy were recorded
from the database system of the hospital. Complete blood
count examinations had been performed on samples
anticoagulated with ethylenediamine tetraacetic acid
(EDTA). Samples had been studied within 2 h after
sampling to prevent time-dependent swelling of platelets
that may be caused by EDTA. The duration and dose of
colchicine and anti-IL-1 treatments for patients with FMF
were recorded.
MPV and other laboratory parameters were compared
between patients with AA amyloidosis and patients with
membranous glomerulonephritis, FSGS, and IgA
nephropathy. Factors affecting MPV were also
determined.
Statistical Package of Social Sciences (SPSS) v: 20.0 was
used for statistical analyses. Distribution characteristics
of the variables were analyzed with Kolmogorov–Smirnov
test. Data were expressed as mean  standard deviation,
standard deviation, median, and 25th–75th interquartile
range or numbers and percentages. Comparisons were
performed with Chi-square test for categoric variables.
For comparison of continuous variables between two
groups, independent-samples t-test and Mann–Whitney U
tests were used. Pearson and Spearmen tests were used
for correlation analyses. A linear regression analysis was
introduced to determine the independent predictors of
MPV. The capacity of MPV values in predicting presence of
AA amyloidosis was analyzed using ROC (receiver
operating characteristics) curve analysis. P values < 0.05
were considered statistically significant.
3. Results
The mean age of the 703 patients that was included in the
study was 42.6  14.3 years. There were 411 male and 292
female patients. The distribution of number of the patients
with regard to the biopsy diagnoses were as follows: FMF

related AA amyloidosis 124 patients, IgA nephropathy
224 patients, membranous glomerulonephritis 188
patients, and FSGS 167 patients. Demographic
characteristics and laboratory values of the patients
according to the biopsy diagnoses are presented in Table
1.
Mean age of the patients with AA amyloidosis was
similar to patients with membranous glomerulonephritis
but significantly higher compared to patients with FSGS
and IgA nephropathy. Female patients were more
prevalent in FSGS group but the majority of the patients
were male in other groups. In AA amyloid group compared
to other groups, mean hemoglobin level was significantly
lower and mean leucocyte and platelet counts were
significantly higher. Mean creatinine level of patients with
AA amyloidosis was significantly higher compared to
patients with FSGS and membranous glomerulonephritis
but similar to patients with IgA nephropathy. Mean
proteinuria level of patients with AA amyloidosis was
similar to patients with FSGS and membranous
glomerulonephritis but higher than patients with IgA
nephropathy. Serum albumin level of patients with AA
amyloidosis was similar to patients with membranous
glomerulonephritis but significantly lower compared to
patients with FSGS and IgA nephropathy. ESR and CRP
values were significantly higher in patients with AA
amyloidosis compared to other groups.
Patients with AA amyloidosis (n = 124) had
significantly lower MPV compared to patients without AA
amyloidosis (n = 579) (7.9  1.2 fL vs. 8.2  0.9 fL
respectively, p = 0.008). Patients with AA amyloidosis had
also significantly lower MPV compared to patients with
each of the other diagnoses (Table 1). Among the AA
amyloid group, 29 patients had previous diagnosis of FMF
and all of them were under colchicine treatment at the
time of biopsy while remaining 95 patients had no
previous diagnosis of FMF and hence was not using
colchicine. Although patients that were using colchicine at
the time of biopsy had higher MPV levels compared to
patients not using colchicine, the difference was not
statistically significant (8.0  1.0 fL vs. 7.8  1.3 fL
respectively, p = 0.506). No patient was using anti IL-1
treatment at the time of biopsy in the AA amyloidosis
group.
Female patients had higher MPV compared to male
patients (8.2  1.0 fL vs. 8.1  1.0 fL respectively, p = 0.04).
In the whole study population MPV was negatively
correlated with platelet count (r = –0.351, p < 0.001). This
correlation was still present when patients with different
diagnoses were evaluated separately and was the most
prominent in AA amyloidosis group (Table 2). MPV levels
were also negatively correlated with ESR (r = –0.162, p =
0.001) and CRP (r = –0.160, p = 0.007). There was no
significant correlation of MPV with other laboratory
parameters including hemoglobin, leucocyte, creatinine,
serum albumin and proteinuria levels. A linear regression
analysis revealed that independent predictors of MPV
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Table 1. Demographic characteristics and laboratory values of the patients at the time of biopsy according to the biopsy diagnoses.
FMF related AA
Focal segmental
Membranous
IgA
amyloidosis
glomerulosclerosis
nephropathy
nephropathy
(n = 124)
(n = 167)
(n = 188)
(n = 224)
40.1  14.1
47.8  14.4
38.1  11.8
Age (years)
46.3  15.4
(p < 0.001)
(p = 0.393)
(p < 0.001)
Males (n, %)
77 (46.1)
104 (55.3)
150 (67.0)
80 (64.5)
(p = 0.002)
(p = 0.126)
(p = 0.723)
12.9  2.1
13.3  2.0
13.0  2.0
Hemoglobin (g/dL) 11.9  2.3
(p = 0.001)
(p < 0.001)
(p < 0.001)
8.3

2.5
7.9

2.6
8.0  2.2
Leucocyte (x109/L) 9.3  3.1
(p = 0.001)
(p < 0.001)
(p < 0.001)
Platelet
277.6  83.0
278.6  79.7
246.6  70.0
357.3  125.5
(x109/L)
(p < 0.001)
(p < 0.001)
(p < 0.001)
Creatinine
1.48  1.35
1.05 + 0.94
1.86  1.49
2.03  2.41
(mg/dL)
(p = 0.02)
(p < 0.001)
(p = 0.458)
Albumin
3.31  0.98
2.66 + 0.72
3.81  0.60
2.47  0.89
(g/dL)
(p < 0.0001)
(p = 0.04)
(p < 0.001)
Proteinuria
4678  7569
7054  11377
2488  2083
6161  5426
(mg/day)
(p = 0.07)
(p = 0.435)
(p < 0.001)
ESR
38.3  32.8
38.7  27.0
28.0  25.9
62.1  34.6
(mm/h)
(p < 0.001)
(p < 0.001
(p < 0.001)
CRP
1.91[0.88–6.34]
0.47[0.28–0.90]
0.31[0.22–0.63]
0.54[0.28–1.52]
(mg/dL)
(p < 0.001)
(p < 0.001)
(p < 0.001)
MPV (fL)
8.2  0.9
8.1  1.0
8.3  0.9
7.9  1.2
(p = 0.01)
(p = 0.04)
(p = 0.001)
P values demonstrate the difference between AA amyloid group and other groups.
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, FMF: Familial Mediterranean fever, MPV: mean platelet volume.
Table 2. Correlation between platelet count and mean platelet
volume at the time of biopsy according to the biopsy
diagnoses.
r value
p
value
–0.351
Whole group
<0.001
–0.408
<
AA amyloid group
0.001
–0.314
<
FSGS group
0.001
Membranous nephropathy
–0.336
<
group
0.001
–0.237
<
IgA nephropathy group
0.001
FSGS: Focal segmental glomerulosclerosis.

were platelet count (β = –0.321, p < 0.001) and CRP (β = –
0.134, p < 0.03).
ROC analysis for MPV showed that the area under the
curve was 0.60, 95% confidence interval: 0.54–0.66, p =
0.001, and the cut-off value of ≤ 8.1 fL had a sensitivity of
62.1% and a specificity of 54.2% to predict AA
amyloidosis.
4. Discussion
This study confirmed the previous results of the studies
that reported low MPV in patients with AA amyloidosis
secondary to FMF in a much larger sample size.
Furthermore, low MPV could not be explained with severe
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proteinuria or low glomerular filtration rate (GFR) in AA
amyloidosis, as patients with AA amyloidosis had
significantly lower MPV levels when compared to patients
with different types of glomerulonephritis with similar
proteinuria or GFR.
Few studies have previously investigated MPV levels in
AA amyloidosis and all concluded that MPV is low in AA
amyloidosis [10,17]. Erdem et al. included 33 AA
amyloidosis patients with different etiologies and
compared MPV levels in AA amyloidosis patients with
control group. Mean MPV was 7.4 fL in AA amyloidosis
group and 8.4 fL in the control group (p < 0.0001) [17].
Ozkayar et al. compared MPV levels of 29 patients with AA
amyloidosis secondary to FMF with MPV levels in amyloid
negative FMF patients and control subjects. Mean MPV of
AA amyloid group was significantly lower (6.9 fL)
compared to amyloid negative FMF patients (10.2 fL) and
control group (9.2 fL) (p < 0.001 for both comparisons)
[10]. Neither of these studies had investigated the
association between MPV levels and amount of 24-h
proteinuria. In another study Sakalli et al reported higher
MPV in patients with proteinuria compared to patients
without proteinuria however authors did not specifically
disclose MPV levels in patients with and without AA
amyloidosis [7]. In a small sample size study investigating
the effect of renal function on MPV in AA amyloidosis, no
significant relationship was found between MPV and GFR
[13]. In our study with the largest sample size that
included 124 AA amyloidosis patients and a total of 703
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patients with glomerulonephritis, we did not observe a
correlation between MPV and proteinuria or renal
function in AA amyloidosis group and in whole study
population.
The results of this study indicate that there should be
other mechanisms responsible from low MPV in AA
amyloidosis rather than proteinuria or renal functions.
Previously some authors argued that severe inflammation
might be directly responsible from low MPV. IL-6, one of
the main inflammatory mediators in FMF [18–20] is the
most widely studied inflammatory marker for MPV and
have a clear effect on stimulating thrombocytosis and
decreasing MPV considering the inverse relation between
platelet count and MPV yielding a constant mass of
platelet [21,22]. Clarke et al, revealed that when
recombinant IL-6 is administered subcutaneously to
patients with advanced malignancy to stimulate
thrombopoiesis, platelet numbers reached to a peak level
at the end of the second week with accompanying
decrease in MPV about 10% [21]. Similarly Van Gameren
et al, observed increased platelet counts and a decrease in
mean MPV value from 8.3 fL to 7.1 fL in patients with
breast and lung cancer with IL-6 treatment [22]. IL-1 and
TNF-alpha are the other inflammatory markers that affect
platelet size and number [23,24]. Anti-TNF-alpha
treatments result in significant increase in MPV levels in
inflammatory conditions [25]. MPV was found to be
negatively correlated with ESR and CRP in patients with
rheumatoid arthritis and inflammatory bowel disease
[26,27]. However, the largest study about the relation
between MPV and CRP come from a population study of
National Health and Nutrition Examination Survey
(NHANES) data in 16,329 subjects revealing a significant
negative correlation between MPV and CRP [28].
In this study we also observed that patients with AA
amyloidosis had significantly higher CRP levels compared
to patients with other glomerular diseases and in
multivariate analysis CRP was one of the few parameters
that predict the MPV levels. We observed that patients
with AA amyloidosis had significantly lower hemoglobin
levels and higher leucocyte and platelet counts compared
to other groups. The high platelet count in AA amyloidosis
patients together with the negative correlation between
platelet count and MPV in this current study strengthens
the hypothesis that inflammatory markers stimulate
thrombopoiesis and result in low MPV. Another probable
explanation of low MPV in inflammation may be related to
consumption of large active platelets in the inflammation
sites like vessel walls and serosal membranes leading to
decreased MPV levels of circulating platelets in
inflammatory diseases like FMF [16,23,29].
However, these hypotheses do not explain why most of
the studies report high MPV in FMF patients without AA
amyloidosis. In this regard the effect of colchicine on MPV
should be considered. It is known that colchicine has the

potential to increase MPV [30]. It is possible that low MPV
in patients with AA amyloidosis, which is a result of
ongoing inflammation, can be explained by severe
inflammation. However, the MPV increasing effect of
colchicine may be more pronounced compared to the MPV
lowering effect of inflammation in patients with FMF
without severe inflammation and no accompanying AA
amyloidosis. In our study AA amyloidosis group included
29 patients that already had a diagnosis of FMF and using
colchicine at the time of biopsy, in addition to 95 subjects
that underwent renal biopsy for nephrotic syndrome and
had no previous diagnosis of FMF and usage of colchicine.
Although we observed higher MPV levels in patients
under colchicine treatment, this difference did not reach
statistical significance probably as a result of low number
of these subjects. In this regard it will be interesting to
determine the changes in MPV values after the
introduction of colchicine and anti Il-1 treatments in
future studies.
The main limitation of this study is related with
retrospective design which leads to lack of reliable data
about several parameters which have the potential to
affect MPV. These parameters are co-morbid conditions
like type 2 diabetes mellitus, acute coronary syndromes,
moderate-to-severe valvular heart disease, smoking
status, hypertension, hypercholesterolemia, liver
diseases, obesity, the metabolic syndrome, hematological
diseases, malignancy, acute and chronic infections, stroke
and usage of statins and antihypertensive drugs. However,
since the study was conducted in large patient population
with similar demographic characteristics and laboratory
values in each group, we believe that these factors are
evenly distributed among the groups.
In conclusion despite the limitation stated above, this
study is the largest study of MPV in patients with biopsy
proven FMF related AA amyloidosis and confirms
previous studies reporting low MPV in AA amyloidosis.
This study clearly indicates that low MPV cannot be
explained with severe proteinuria and impaired renal
function. Considering the low hemoglobin, high platelet
counts and high levels of inflammatory markers in AA
amyloidosis, the low MPV is probably related with the
direct effect of inflammation on bone marrow.
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